Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology
What is the clinical utility of the Combined Positive Score (CPS) for PDL-1 expression when considering pembrolizumab for gastric cancer?
How do you interpret results when IHC is < 1% but CPS > 1?
Answer from: Medical Oncologist at Academic Institution
From multiple studies, it is very clear that higher staining for PDL-1 on tumors and immune cells (combined expression, resulting in the CPS (combined positive score)) is correlated with increased Response Rate, PFS and clinical benefit of anti-PD1 drugs. Pembrolizumab is approved for gastric ...
Sign in or Register to read more